Axsome Therapeutics Inc (AXSM)
76.54
-0.82
(-1.05%)
USD |
NASDAQ |
May 17, 16:00
76.54
0.00 (0.00%)
After-Hours: 20:00
Axsome Therapeutics Cash from Financing (Quarterly): -1.187M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -1.187M |
| December 31, 2023 | -0.002M |
| September 30, 2023 | 33.37M |
| June 30, 2023 | 246.08M |
| March 31, 2023 | 51.56M |
| December 31, 2022 | 1.066M |
| September 30, 2022 | 176.95M |
| June 30, 2022 | 75.46M |
| March 31, 2022 | 31.10M |
| December 31, 2021 | 0.6908M |
| September 30, 2021 | 0.4387M |
| June 30, 2021 | 1.971M |
| March 31, 2021 | 8.029M |
| December 31, 2020 | 2.09M |
| September 30, 2020 | 27.43M |
| June 30, 2020 | 12.27M |
| March 31, 2020 | 0.6298M |
| December 31, 2019 | 193.89M |
| September 30, 2019 | 0.5188M |
| Date | Value |
|---|---|
| June 30, 2019 | 19.82M |
| March 31, 2019 | 38.16M |
| December 31, 2018 | 8.542M |
| September 30, 2018 | 0.7898M |
| June 30, 2018 | 1.396M |
| March 31, 2018 | -0.6934M |
| December 31, 2017 | 8.639M |
| September 30, 2017 | 0.1299M |
| June 30, 2017 | 0.0748M |
| March 31, 2017 | 15.04M |
| December 31, 2016 | 9.953M |
| September 30, 2016 | 0.0147M |
| June 30, 2016 | 0.00 |
| March 31, 2016 | |
| December 31, 2015 | 45.67M |
| September 30, 2015 | 0.1335M |
| June 30, 2015 | 6.832M |
| March 31, 2015 | 0.2417M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.187M
Minimum
Mar 2024
246.08M
Maximum
Jun 2023
44.11M
Average
10.15M
Median
Cash from Financing (Quarterly) Benchmarks
| Krystal Biotech Inc | 10.58M |
| Catalyst Pharmaceuticals Inc | 141.05M |
| Vertex Pharmaceuticals Inc | -357.50M |
| Vistagen Therapeutics Inc | 93.52M |
| ADMA Biologics Inc | -1.447M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -53.47M |
| Cash from Investing (Quarterly) | -0.098M |
| Free Cash Flow | -193.34M |
| Free Cash Flow Per Share (Quarterly) | -1.130 |
| Free Cash Flow to Equity (Quarterly) | -54.18M |
| Free Cash Flow to Firm (Quarterly) | -52.48M |
| Free Cash Flow Yield | -5.45% |